



(51) International Patent Classification:

A61K 35/18 (2006.01) *A61K 9/48* (2006.01)
A61P 35/02 (2006.01) *A61K 38/48* (2006.01)

(21) International Application Number:

PCT/EP2013/055928

(22) International Filing Date:

21 March 2013 (21.03.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/613,660 21 March 2012 (21.03.2012) US

(71) Applicant: ERYTECH PHARMA [FR/FR]; 60 avenue Rockefeller, F-69008 Lyon (FR).

(72) Inventor: GODFRIN, Yann; 23 rue Henri Gorjus, F-69004 Lyon (FR).

(74) Agents: COLOMBET, Alain et al.; Lavoix, 62, rue de Bonnel, F-69003 Lyon (FR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: MEDICAMENT FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML)

(57) Abstract: The present invention relates to the therapeutic treatment of Acute Myeloid Leukemia (AML). It concerns in particular a novel composition for the treatment of this cancer and an associated therapeutic treatment method. The invention concerns a suspension of erythrocytes encapsulating asparaginase as a medicament for treating Acute Myeloid Leukemia (AML). The invention also concerns a method for treating Acute Myeloid Leukemia (AML) comprising administering an efficient amount of a suspension of erythrocytes encapsulating asparaginase.

